| Followers | 10 |
| Posts | 1467 |
| Boards Moderated | 0 |
| Alias Born | 07/16/2006 |
Wednesday, September 24, 2014 1:24:44 PM
I posted this before, but it goes with my last post.
Forzanano, I think you stock rise is wrong. Look at the chart for ICPT! I think our chart will blow theirs away! The Ebola thing is big news, a sexy news story, but the FLU is a magnitude bigger. Here is what I PREDICT IMHO,
1. Tox starts on FLUCIDE.
2. NNVC makes enough Ebolacide to have a good test in Africa.
3. No Tox is showing up in Flucide tests at the time Ebolacide is ready for testing.
4. WHO elects to use Ebolacide based on the Flucide safety profile, shown to that date.
5. Ebolacide works better than anything else, It did some good in the army tests, now with the II added, it does even better.
6. Dr. Diwan is now at the front of the pack and is green lighted to develop other Ebolacides for other strains of the ebola virus. Remember that they have seen 400 mutatios so far. Learing and Practicing are thing that is always going on in medicine.
7. Peoples lives are saved and our belief in the science DR. Seymour and Diwan is proven!
Then, based on the safety profile of Ebolacide, Flucide is fast tracked and approved. IMHO
Forzanano, I think you stock rise is wrong. Look at the chart for ICPT! I think our chart will blow theirs away! The Ebola thing is big news, a sexy news story, but the FLU is a magnitude bigger. Here is what I PREDICT IMHO,
1. Tox starts on FLUCIDE.
2. NNVC makes enough Ebolacide to have a good test in Africa.
3. No Tox is showing up in Flucide tests at the time Ebolacide is ready for testing.
4. WHO elects to use Ebolacide based on the Flucide safety profile, shown to that date.
5. Ebolacide works better than anything else, It did some good in the army tests, now with the II added, it does even better.
6. Dr. Diwan is now at the front of the pack and is green lighted to develop other Ebolacides for other strains of the ebola virus. Remember that they have seen 400 mutatios so far. Learing and Practicing are thing that is always going on in medicine.
7. Peoples lives are saved and our belief in the science DR. Seymour and Diwan is proven!
Then, based on the safety profile of Ebolacide, Flucide is fast tracked and approved. IMHO
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
